Clinical Trial Search

Primary: Change in Vasoreactivity During Exercise at Baseline and 8-week Visits. — 0.031; 0.028 cm s-1 mmHg-1/mmHg CO2

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 6; 6; 7; 3 Participants

Primary: Number of Participants With a Dose Limiting Toxicity (DLT), Triggered by Occurrence in the First 24 Hours After Human Mesenchymal Stem Cell (hMSC) Infusion of Grade ≥3…

Primary: Feasibility of Same-session MRI-only Simulation as Defined as More Than 70% of Patients Receiving at Least 70% of Their Scheduled Treatment Fractions on the First…

Primary: Change From Baseline in Hamilton Depression Rating Scale 17-item Version (HAMD17) Through Treatment — -8.0; -5.7; -0.8; -2.6 score on a scale

Primary: Overall Response Rate — 0; 0; 5; 4 Participants

Primary: Number of Participants With Grade 3 Adverse Reactions or Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 24 Hours After the First…

Primary: The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA…

Primary: Percentage of Participants Experiencing Treatment-emergent Adverse Events During the 2-stage Study Sequence (Safety) — 60 percentage of participants

Primary: Number of Participants Who Experienced a Dose-limiting Toxicity — 0 Participants

Primary: Number of Participants Who Chose Active Monitoring (AM). — 28; 18 Participants

Primary: Area Under the Curve (AUC) for C-reactive Protein (CRP) — 133 mg*day/L

Primary: Number of Participants With Death or Neurodevelopmental Impairment — 126; 110 Participants

Primary: Part A, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Midazolam — 57.2; 42.1 hour*nanogram per milliliter (h*ng/mL)

Primary: Overall Survival (OS) — 9.6; 14.7 months — p=<0.001